WuXi Biologics Germany GmbH is a 100% subsidiary of WuXi Biologics Ireland Limited and is registered in the Cologne commercial register under HRB 100021. As a contract research, development and manufacturing organization (CRDMO) it provides end-to-end solutions to discover, develop and manufacture biological medicinal products from concept to commercialisation. In the 2023 financial year the company generated revenue of EUR 9,998,037.46, primarily from initial clinical fill-finish batches and customer projects at its Leverkusen site. At the balance sheet date the company employed 397 persons and executed substantial investments, increasing fixed assets by EUR 64.40 million to EUR 359,259,883.45 as of 31 December 2023.
die Bereitstellung eines umfassenden, integrierten und hochgradig anpassbaren Dienstleistungsangebots für die Entwicklung und Herstellung von Biologika-Arzneimitteln. Das Unternehmen ist Teil von WuXi Biologics, das globale offene Technologieplattformen und Gesamtlösungen anbietet, um die Entdeckung, Entwicklung und Herstellung von Biologika vom Konzept bis zur kommerziellen Herstellung zu ermöglichen.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 100021 (as of 30 October 2026)
| Name | Type | City |
|---|---|---|
| Wei Guo | Geschäftsführer(in) | Shanghai |
| Jürgen Hinderer | Geschäftsführer(in) | Leverkusen |
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 100021 (as of 30 October 2026)
| Date | Event Type | Event |
|---|---|---|
| 01.12.2025 | Business Address Change | Breidenbachstraße 56, 51373 Leverkusen |
| 31.01.2025 | Business Address Change | Chempark Leverkusen, Building D501, Kaiser-Wilhelm-Allee 101-103, 51373 Leverkusen |
| 22.07.2020 | Business Address Change | Chempark Leverkusen, Building D201, Tor 133, 51368 Leverkusen |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 29.11.2019 | Share Capital Set | — | 25.000 € |
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 100021 (as of 30 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | €5,554,681 | -€76,460,712 | €391,333,523 | — |
| 2023 | €9,998,037 | -€44,423,988 | €380,111,172 | 377 |
| 2022 | €6,393,042 | €33,148,168 | €318,725,451 | 277 |
| 2021 | €0 | -€30,409,272 | €254,926,466 | 121 |
| 2020 | Rohergebnis€1.8M2 | -€3,863,253 | €111,034,600 | 20 |
| 2019 | — | -€2,949 | €224,851 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 100021 (as of 30 October 2026)
APOSAN GmbH
Köln · Herstellung von pharmazeutischen Grundstoffen
LTS LOHMANN Therapie-Systeme AG.
Andernach · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
Guerbet GmbH
Sulzbach · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €37,598,780 | 62.2% |
| Material Costs | €1,479,717 | 2.4% |
| Depreciation | €9,904,935 | 16.4% |
| Interest & Similar | €11,417,472 | 18.9% |
